Posters

First results after 3rd generation iStent® inject ‘W’ implantation in glaucomatous eyes – 3 months of follow-up

Poster Details

First Author: F.Rufer GERMANY

Co Author(s):    K. Pluta   B. Alokla   D. Holland              

Abstract Details

Purpose:

To evaluate the implantation procedure and IOP-lowering effect of latest 3rd generation iStent® inject ‘W’ implantation in glaucomatous eyes.

Setting:

Single Center Single Surgeon Study

Methods:

17 eyes of 14 patients with glaucoma aged 53–90 years (mean 69±12 years) were included. In all eyes, 2 of the latest 3rd generation iStent® inject ‘W’ with a larger base diameter (360 µm) compared to 2nd generation iStent® inject (base diameter 230 µm) were implanted into the trabecular meshwork (TM). The IOP was measured preoperatively, postoperatively after 1 day, 1 month, and 3 months after the implantation. Complications during the implantation process as well as the IOP changes and the number of required antiglaucomatous drugs were recorded.

Results:

15 eyes were pseudophakic, 2 eyes were phakic and underwent combined cataract surgery. In two eyes, transient IOP spikes (28 mmHg and 34 mmHg) were present during the first postoperative day. No further complications occurred and 2 stents could be implanted successfully into the trabecular meshwork in all cases. There were no overimplantations (implantation too deep into the TM). The mean preoperative IOP (mmHg) was 22.2±7.4. The mean first postoperative day IOP was (13.9±4.6). Further follow-up was not available at time of the abstract submission and will be added.

Conclusions:

A significant IOP reduction was observed one day after the iStent® inject ‘W’ implantation. No vision threatening complications occurred. In contrast to the 2nd generation iStent® inject implantations, no overimplantations were seen. Whether this leads to a better IOP reduction compared to the 2nd generation iStent® inject, has to be evaluated in comparative trials.

Financial Disclosure:

travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented